retatrutide type 2 diabetes trial results Phase 2: Weight Loss and Key Findings – Bolt Pharmacy A New Obesity Drug Delivered

#ObesityTherapeutics #GLP1 #TernsPharma #ObesityTreatment #ClinicalTrials #MetabolicHealth Terns Pharmaceuticals Halts Obesity Program After Underwhelming Phase 2 Data for Oral GLP-1 (TERN-601) Terns Pharmaceuticals announced topline 12-week Phase 2 FALCON results for its once-daily oral GLP-1 receptor agonist TERN-601 in adults with obesity (BMI 2750 kg/m, without diabetes), showing modest placebo-adjusted weight loss of 4.6%, below internal efficacy targets

Both medications commonly cause gastrointestinal side effects and carry important warnings

Patients should follow their providers instructions and medication guidance for missed doses

Demand had so thoroughly outpaced manufacturing capacity that continuity of care for people with type 2 diabetes was at risk and prescribers were urged not to initiate GLP-1 therapies outside their approved indications while constraints remained in place

If the side effects do not get better or get worse, make sure you talk to a healthcare professional

Following a Mediterranean diet is associated with better blood sugar control